You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股表現》加科思藥業(01167.HK)暗盤高開18%報16.48元
阿思達克 12-18 16:17
根據輝立交易平台顯示,下周一(21日)掛牌的加科思藥業(01167.HK)暗盤高開17.7%報16.48元獲承接,現造20.9元,較上市價14元,高49%,成交100萬股。

加科思是一家仍處於臨床階段製藥公司,專注於創新腫瘤療法自主研發。是次上市共發售9,647.61萬股,並已引入包括LAV Funds、Matthews Funds、哈德遜灣資本、Octagon Investments等6名基石投資者,合共認購3,322.08萬股;其中10%公開發售獲逾298倍超購,已啟動回撥機制佔比增至50%,認購一手中籤率15%,股份以招股範圍(12-14元)上限定價,料集資淨額約12.63億元,其中88%用作產品的臨床開發和商業化,8%用於建造符合GMP標準內部生產設施。上市聯席保薦人分別為高盛及中金。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account